Bolt Biotherapeutics is a world-class brand that fosters a community of fearless innovators dedicated to transforming cancer treatments and addressing the unmet medical needs of patients. They leverage the power of the innate and adaptive immune systems to achieve long-term tumor remissions. By pioneering a new category of targeted immunotherapies, Bolt combines the precision of antibody targeting with the activation of the immune systems in the tumor microenvironment.

Their approach involves developing Boltbody™ ISACs, such as BDC-1001, which is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer. Additionally, Bolt has a robust pipeline of immune-stimulating, myeloid-engaging therapeutics that utilize their Myeloid Modulator Platform. With a focus on innovation, Bolt Biotherapeutics aims to deliver transformative treatments to cancer patients, guided by their world-class team of experts